News

Bio Pharma APAC
biopharmaapac. com > news > 55 > 8043 > promptbio-launches-agentic-ai-platform-to-accelerate-scientific-discovery. html

Prompt Bio Launches Agentic AI Platform to Accelerate Scientific Discovery

3+ hour, 15+ min ago  (316+ words) Bio Pharma APAC - Prompt Bio Launches Agentic AI Platform to Accelerate Scientific Discovery 11 June 2026 | Thursday | News The Prompt Bio Platform combines conversational AI with multi-agent orchestration to accelerate discovery from hypotheses to insights Prompt Bio, a California-based leader in AI…...

Symbols: btc-usd
Bio Pharma APAC
biopharmaapac. com > news > 120 > 7992 > leica-biosystems-indica-labs-and-lunit-advance-ai-powered-digital-pathology-for-pd-l1-biomarker-analysis. html

Leica Biosystems, Indica Labs, And Lunit Advance AI Powered Digital Pathology For PD L1 Biomarker Analysis

1+ week, 6+ day ago  (161+ words) Bio Pharma APAC - Leica Biosystems, Indica Labs, And Lunit Advance AI Powered Digital Pathology For PD L1 Biomarker Analysis 29 May 2026 | Friday | News - Innovations In Magnetic Resonance Imaging Introduced By United Imaging - 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know…...

Symbols: btc-usd
Bio Pharma APAC
biopharmaapac. com > news > 32 > 7930 > benchling-launches-antibody-rd-platform-to-accelerate-biologics-discovery-and-development. html

Benchling Launches Antibody R&D Platform To Accelerate Biologics Discovery And Development

4+ week, 22+ hour ago  (217+ words) 13 May 2026 | Wednesday | News Benchling Biologics addresses this across each stage of the workflow: Discovery: Process sequencing data at scale Design: Configure any format, same day Scientists are evolving antibody formats faster than most systems can accommodate and existing tools aren't…...

Symbols: nasdaq:absi,d05.S0,u11.S0,z74.S0,blu.si,575.S0
Bio Pharma APAC
biopharmaapac. com > news > 32 > 7841 > synthetic-design-lab-introduces-logic-gated-synthbody-platform-redefining-precision-protein-therapeutics. html

Synthetic Design Lab Introduces Logic Gated SYNTHBODY Platform Redefining Precision Protein Therapeutics

1+ mon, 2+ week ago  (134+ words) 20 April 2026 | Monday | News Similar early results were observed in a Non-Hodgkin's Lymphoma (NHL)-targeting SYNTHBODY" construct, and a high-throughput SYNTHBODY ENGINE" approach is being used to rapidly generate and optimize multiple solid tumor SYNTHBODY" ADCs, supporting the platform's broad applicability…...

Symbols: nasdaq:snti